R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Bevacizumab for recurrent ependymoma.
Richard M. Green,Timothy F. Cloughesy,Roger Stupp,Lisa M. DeAngelis,Emily Woyshner,Douglas E. Ney,Douglas E. Ney,Andrew B. Lassman +7 more
TL;DR: The radiographic response rate to bevacizumab-containing regimens is high, and a prospective study is warranted to assess this response rate in patients with recurrent glioblastoma.
Journal ArticleDOI
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study
Leida M. Lamers,Roger Stupp,Martin J. van den Bent,Maiwenn Al,Thierry Gorlia,Jean-Blaise Wasserfallen,Nicole Mittmann,Soo Jin Seung,Ralph Crott,Carin A. Uyl-de Groot +9 more
TL;DR: The study aimed to compare the cost‐effectiveness of concomitant and adjuvant temozolomide for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective.
Journal ArticleDOI
ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA
Journal ArticleDOI
MGMT methylation status: the advent of stratified therapy in glioblastoma?
TL;DR: Determination of the methylation status of the MGMT promoter may become the first molecular diagnostic tool to identify patients most likely to respond that will allow individually tailored therapy in glioblastoma.
Journal ArticleDOI
Pregabalin in patients with primary brain tumors and seizures: a preliminary observation.
TL;DR: Pregabalin appears to have a promising effectiveness in this setting, even as a monotherapy, and a prospective controlled trial is embarked on based on these results.